NANOPHARMACEUTICS: A NOVEL DRUG DELIVERY TECHNOLOGY
Main Article Content
Keywords
Drug Delivery Systems, Liposomes, Polymeric Nanoparticles and Solid Lipid Nanoparticles.
Abstract
Nanopharmaceutics, an evolving branch of nanotechnology, offers a revolutionary and innovative approach to drug delivery systems. Nanopharmaceutics offering promising solutions to the challenges faced by conventional pharmaceutical formulations. This review provides an overview of recent advancements in nanopharmaceutics, focusing on the potential benefits it brings to the field of drug delivery. Nanopharmaceutics employs nanotechnology-based platforms, such as liposomes, micelles, polymeric nanoparticles, and solid lipid nanoparticles, to encapsulate drugs at the nanoscale level. These nanocarriers, often ranging from 1 to 100 nanometers in size, can encapsulate therapeutic agents, including drugs and biological molecules, offering controlled release, improved solubility of poorly water-soluble drugs, improved bioavailability, and targeted delivery to specific tissues or cells. By facilitating site-specific drug delivery, nanopharmaceutics not only enhances therapeutic outcomes but also reduces drug doses, potentially leading to cost savings and improved patient compliance. The reviw also highlights various breakthroughs in nanopharmaceutics, such as novel nanoparticle synthesis methods, surface functionalization techniques, and controlled release strategies. Finally concludes by highlighting the promising prospects of nanopharmaceutics in transforming drug delivery systems. As research continues to advance in this field, nanopharmaceutics holds immense potential to revolutionize the treatment of various diseases, providing safer, more effective, and personalized therapies. This innovative approach has the potential to reshape the landscape of pharmaceutical development and improve patient outcomes across a wide range of medical conditions.
References
2. Basu B, Garala K, Bhalodi R, Joshi B, Mehta K (2010) Solid lipid nanoparticles: A promising tool for drug delivery system. J Pharm Res 3(1): 84-92.
3. Bawa R (2009) Nanopharmaceuticals for Drug delivery-A review. Touch Briefings 6: 122- 127.
4. Bikram M, Gobin AM, Whitmire RE, West JL (2007) Temperature-sensitive hydrogels with SiO2–Au nanoshells for controlled drug delivery. J ControlledRelease 123(3): 219–227.
5. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C (2007) Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev59 (6): 454-477.
6. Bowman D, Marino AD, Sylvester DJ. The patent landscape of nanomedicines. Med. Res. Arch. 2017;5. 20. Rocha RA, Muccilo ENS (2003).
7. Cesur H, Rubinstein I, Pai A, Onyuksel H (2009) Selfassociatedindisulam in phospholipid-based nanomicelles: A potential nanomedicine for cancer. Nanomedicine 5(2): 178-183.
8. Dandagi P, Keru S, Mastiholimath V, Gadad A, Kulkarni A (2009) Polymeric ocular nanosuspension for controlled release of acyclovir: in vitro release and ocular distribution. Iran J Pharm Res 8: 79-86
9. Donald EO, Peppas NA (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307(1): 93-102
10. Dutta P, Dey J (2011) Drug solubilization by amino acid based polymeric nanoparticles: Characterization and biocompatibility studies. Int J Pharm 421: 353-363.
11. Firme III CP, Bandaru PR (2010) Toxicity issues in the application of carbon nanotubes to biological systems. Nanomedicine 6(2): 245-256.
12. Gao F, Zhang Z, Bu H, Huang Y, Gao Z (2011) Nanoemulsion improves the oral absorption of candesarten.
13. Harris JM, Chess RB (2003) Effect of PEGylation on pharmaceuticals. Nat RevDrug Discov 2:214–221
14. Hollis CP, Weiss HL, Leggas M, Evers BM, Gemeinhart RA, Li T. Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and ima.
15. Jain, K.K. The role of nanobiotechnology in drug discovery. Drug DiscoveryToday (2005)10(21).1435-42.
16. Kayser O, Lemke A, Hernandez-Trejo (2005) The impact of nanobiotechnology on the development of new drug delivery systems. Curr Pharm Biotechnol 6(1): 3 -53
17. Kumar A, Jena PK, Behera S, Lockey RF, Mohapatra S, et al. (2010) Multifunctional magnetic nanoparticles for targeted delivery. Nanomedicine 6(1): 64-69Characterization and biocompatibility studies. Int J Pharm 421: 353-363.
18. Liu M, Kono K, Frechet JMJ (1999) Water soluble dendrimer poly (ethylene glycol) star like conjugates as potential.
19. Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z. Polysaccharides-based nanopar ticles as drug delivery systems. Adv Drug Deliv Rev. 2008;60:1650–62
20. Md. Zubayer Hossain Saad et al.: Nanopharmaceuticals: A New Perspective of Drug Delivery System, Asian Journal of Biomedical and Pharmaceutical Sciences 2(14) 2012, 11-20
21. Moritz B, Ruppert C, Schmeh T, Guenther A, Betz T et al. (2011) Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro. Nanomedicine 7(3): 341-350.
22. Otsuka H, Nagasaki Y, Kataoka K (2003) PEGylated nanoparticles for biological and pharmaceutical applications.
23. Panda BP, Varaprasad R, Priyanka K, Swain RP. Current trends in design and development of nanopharmaceutical dosage forms. BioequivBioavailab Int J2017;1:104.
24. Rasoulianboroujeni M, Kupgan G, Moghadam F, et al. Development of a DNA-liposome complex for gene delivery applications. Mater. Sci. Eng. C. 2017;75:191–197
25. Rocha RA, Muccilo ENS (2003) Physical and chemical properties of nanosized powders of gadolinia-doped ceria prepared by the cation complexation technique. Mater Res Bull 38: 1979- 1986
26. Roman JA, Niedzielko TL, Haddon RC, Parpura V, Floyd CL. Single-walled carbon nanotubes chemically functionalized with polyethylene glycol promote tissue repair in a rat model of spinal cord injury. J. Neurotrauma. 2011;28(11):2349–2362.
27. Sagar. Or et.al., Nanoparticles: Emerging carriers for drug delivery, Saudi Pharmaceutical Journal Volume 19, Issue 3, July 2011.
28. Said Soflaei, In Vitro Antiparasitic and Apoptotic Effects of Antimony Sulfide Nanoparticles on Leishmania infantum, Journal of Parasitology Research Volume 2012 (2012), Article ID 756568 (1-7)
29. Sershen SR, Westcott SL, West JL, Halas NJ (2001) An optomechanical nanoshell-polymer composite. Appl Phys B Lasers Opt 73:37
30. Shen X, Yu D, Zhu L, Branford-White C, White K, et al. (2011) Electrospun diclofenac sodium loaded Eudragit® L 100-55 nanofibers for colon-targeted drug delivery. Int J Pharm 408(1-2): 200-207.
31. Subedi RK, Kang KW, Choi H (2009) Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J Pharm Sci 37(3-4): 508–513.
32. Vladimir PT (2006) Nanoparticulate as Drug Delivery. Imperial College Press 499-506.
33. Wissing SA, Kayser O, Muller RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257–1272
34. Wu Z, Wu Z-K, Tang H, Tang L-J, Jiang J-H. Activity-based DNA-gold nanoparticle probe as colorimetric biosensor for DNA methyltransferase/glycosylase assay. Anal. Chem. 2013;85(9):4376–4383ge-guided drug delivery. J. Control. Release. 2013;172(1):12–21
35. Yang J, Lee H, Hyung W, Park SB, Haam S (2006) Magnetic PECA nanoparticles as drug carriers for targeted delivery: synthesis and release characteristics. J Microencapsul 23:203–212
36. Yang W, Cheng Y, Xu T, Wang WL, Wen LP (2009) Targeting cancer cells with biotin dendrimer conjugates. Eur J Med Chem 44(2): 862-868.
37. Yoo HS, Kim TG, Park TG. Surface-functionalized electrospun nanofibers for tissue engineering and drug delivery. Adv Drug Deliv Rev2009;61:1033-42.
38. Zanello LP, Zhao B, Hu H, Haddon RC. Bone cell proliferation on carbon nanotubes. Nano Lett. 2006;6(3):562–567.
39. Zhang X, Gan Y, Gan L, Nie S, Pan W (2008) PEGlyated nanostructured lipid carriers loaded with 10-hydroxycamptothecin: An efficient carrier with enhanced anti-tumour effects against lung cancer. J Pharm Pharmacol 60(8): 1077-1087.